血清sCD163水平与糖尿病性骨质疏松的关系

摘要
图/表
参考文献(20)
相关文章 (15)

全文: PDF (613 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨糖尿病（DM）患者骨密度（BMD）变化与血清可溶性血红蛋白清道夫受体（sCD163）的关系。方法选择2015 年1 月~2016年4 月在解放军第425医院就诊的2型糖尿病患者82例为糖尿病组，再分为骨质疏松组（45例）和非骨质疏松组（37例），同时选取健康人30例作为对照组。双能X线骨密度仪测定受试者腰椎L1~L4的BMD，全自动生化分析仪测定受试者空腹血糖（FPG）、糖化血红蛋白（HbA1c），ELISA法测定受试者血清sCD163水平。结果糖尿病组FGP、HbA1c、sCD163均高于对照组，差异有统计学意义（P < 0.05）；糖尿病组的BMD低于对照组，差异有统计学意义（P < 0.05）。糖尿病骨质疏松组的sCD163水平高于非骨质疏松组，而骨质疏松组的BMD水平低于非骨质疏松组，差异有统计学意义（P < 0.05）。Pearson相关性分析显示：sCD163水平与BMD呈负相关（r= -0.880，P < 0.05）。Logistic回归分析结果表明sCD163是糖尿病性骨质疏松的风险因素（OR = 1.490，P < 0.05）。结论血清sCD163的变化与糖尿病骨质疏松的发生密切相关。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	陈爱宝1 曾国庆1 龚琦2 杨学洪1 穆继宏1

关键词 ：糖尿病, 骨质疏松, 骨密度, 可溶性血红蛋白清道夫受体

Abstract：Objective To investigate the correlation of the bone mineral density (BMD) in patients with type 2 diabetes mellitus with sCD163. Methods From January 2015 to April 2016, in 425th Hospital of PLA, 82 patients with type 2 diabetes mellitus were selected as DM group, DM group was divided into osteoporotic DM group (45 cases) and non-osteoporotic DM group (37 cases), at the same time, 30 healthy persons were enrolled as the control group. BMD of lumbar span (L1-L4) was measured with dual energy X-ray absorptiometry, the levels of FPB and HbA1c were analysed by automatic biochemistry analyzer. The serum level of sCD163 was detected by ELISA. Results The levels of FGP, HbA1c, sCD163 in DM group were significantly higher than those in control group (P < 0.05). The BMD in DM group was significantly lower than that in control group (P < 0.05). The level of sCD163 in osteoporotic DM group was significantly higher than that in non-osteoporotic DM group (P < 0.05), and the level of BMD more declined in osteoporotic DM group than that in non-osteoporotic DM group (P < 0.05). Furthermore, the result of Pearson correlation analysis indicated that BMD was negatively correlated with sCD163 (r = -0.880, P < 0.05). Logistic regression analysis indicated that in DM patients sCD163 was the risk factor for osteoporosis (OR = 1.490, P < 0.05). Conclusion The increased level of sCD163 is related to the osteoporosis in DM.

Key words： Diabetes mellitus Osteoporosis Bone mineral density sCD163

基金资助:海南省三亚市医疗卫生科技创新项目（2014YW46）。

通讯作者: 穆继宏（1983.4-），男，博士；研究方向：创伤骨科。

作者简介: 陈爱宝（1977.6-），男，副主任医师；研究方向：创伤骨科。

引用本文:

陈爱宝1 曾国庆1 龚琦2 杨学洪1 穆继宏1. 血清sCD163水平与糖尿病性骨质疏松的关系[J]. 中国医药导报, 2017, 14(27): 101-104.
CHEN Aibao1 ZENG Guoqing1 GONG Qi2 YANG Xuehong1 MU Jihong1. Relationship of bone density with sCD163 in diabetic osteoporosis. 中国医药导报, 2017, 14(27): 101-104.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2017/V14/I27/101

[1] Blakytny R，Spraul M，Jude EB. Review：the diabetic bone： a cellular and molecular perspective [J]. Int J Low Extrem Wounds，2011，10（1）：16-32.
[2] Jung JK，Kim HJ，Lee HK，et al. Fracture incidence and risk of osteoporosis in female type 2 diabetic patients in Korea [J]. Diabetes Metab J，2012，36（2）：144-150.
[3] Redlich K，Smolen JS. Inflammatory bone loss： pathogenesis and therapeutic intervention [J]. Nat Rev Drug Discov，2012，11（3）：234-250.
[4] Wang TT，He CQ，Yu XJ. Pro-inflammation cytokines： new potential therapeutic targets for obesity-related bone disorders [J]. Curr Drug Targets，2017. [Epub ahead of print].
[5] Colafrancesco S，Priori R，Alessandri C，et al. The hyperferritinemic syndromes and CD163：a marker of macrophage activation [J]. Isr Med Assoc J，2014，16（10）：662-663.
[6] Deichgr?覸ber P，Witte DR，M?覬ller HJ，et al. Soluble CD163，adiponectin，C-reactive protein and progression of dysglycaemia in individuals at high risk of type 2 diabetes mellitus：the ADDITION-PRO cohort [J]. Diabetologia，2016，59（11）：2467-2476.
[7] Samuelsson M，Dereke J，Svensson MK，et al. Soluble plasma proteins ST2 and CD163 as early biomarkers of nephropathy in Swedish patients with diabetes，15-34 years of age：a prospective cohort study [J]. Diabetol Metab Syndr，2017，9：41.
[8] Kobayashi Y，Yoshida S，Nakama T，et al. Overexpression of CD163 in vitreous and fibrovascular membranes of patients with proliferative diabetic retinopathy：possible involvement of periostin [J]. Br J Ophthalmol，2015，99（4）：451-456.
[9] 中华医学会糖尿病学分会.中国2型糖尿病防治指南（2010年版）[J].中国糖尿病杂志，2012，20（1）：S1-S37.
[10] 中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊治指南（2011）[J].中国骨质疏松和骨矿盐疾病杂志，2011，4（1）：2-17.
[11] Dede AD，Tournis S，Dontas I，et al. Type 2 diabetes mellitus and fracture risk [J]. Metabolism，2014，63（12）：1480-1490.
[12] Wongdee K，Krishnamra N，Charoenphandhu N. Derangement of ca1cium metabolism in diabetes mellitus：negative outcome from the synergy between impaired bone turnover and intestinal ca1cium absorption [J]. J Physiol Sci，2017，67（1）：71-81.
[13] Sapa A，Rak A，Wybieralska M，et al. Diagnostic usefulness of sCD163，proca1citonin and neopterin for sepsis risk assessment in critically ill patients [J]. Adv Clin Exp Med，2017，26（1）：101-108.
[14] Parkner T，S?覬rensen LP，Nielsen AR，et al. Soluble CD163：a biomarker linking macrophages and insulin resistance [J]. Diabetologia，2012，55（6）：1856-1862.
[15] Cinkajzlová A，Lacinová Z，Klou■ková J，et al. An alternatively activated macrophage marker CD163 in severely obese patients：the influence of very low-calorie diet and bariatric surgery [J]. Physiol Res，2017 Apr 12. [Epub ahead of print]
[16] Kobayashi Y，Yoshida S，Nakama T，et al. Overexpression of CD163 in vitreous and fibrovascular membranes of patients with proliferative diabetic retinopathy：possible involvement of periostin [J]. Br J Ophthalmol，2015，99（4）：451-456.
[17] 王祥德，郑红波. 糖尿病动脉粥样硬化患者血清sCD163和oxLDL 检测的临床意义[J].现代实用医学，2013，25（5）：520-521.
[18] Ruscitti P，Cipriani P，Carubbi F，et al. The role of IL-1β in the bone loss during rheumatic diseases [J]. Mediators Inflamm，2015，2015：782382.
[19] Roy B，Curtis ME，Fears LS，et al. Molecular mechanisms of obesity-induced osteoporosis and muscle atrophy [J]. Front Physiol，2016，29（7）：439. eCollection 2016.
[20] Liu Y，Almeida M，Weinstein RS，et al. Skeletal inflammation and attenuation of Wnt signaling，Wnt ligand expression，and bone formation in atherosclerotic ApoE-null mice [J]. Am J Physiol Endocrinol Metab，2016，310（9）：E762-E773.